Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01367600 · ClinicalTrials.gov registry record · Phase 3
Open-Label Treatment Extension of Protocol MNTX 301
A Phase 3 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 27
- Enrollment target
NCT01367600 is a Phase 3 study that has completed, run by Bausch Health Americas. The registered enrollment target is 27 participants.
The verdict
NCT01367600, a Phase 3 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 27 participants
- Enrollment target
Study Summary
This study is an open-label extension allowing patients who have completed Protocol MNTX 301 to continue to receive SC MNTX.
Interventions
- DRUG SC Methylnaltrexone (MNTX)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2003-02 |
| Est. Completion | 2005-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01367600
The ClinicalTrials.gov registry entry for NCT01367600 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SC Methylnaltrexone (MNTX) is the first listed.
NCT01367600 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01367600 about?
NCT01367600 is a clinical study titled "Open-Label Treatment Extension of Protocol MNTX 301". This study is an open-label extension allowing patients who have completed Protocol MNTX 301 to continue to receive SC MNTX.
What is the current status of trial NCT01367600?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 27 participants. The study started on 2003-02. Estimated completion is 2005-02.
What interventions are being tested in trial NCT01367600?
The interventions under investigation include: SC Methylnaltrexone (MNTX) (DRUG).
Who is sponsoring clinical trial NCT01367600?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.